Metastatic1. OVATURE (OVArian TUmor REsponse) studyMulti-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy Sponsor: Marshall Edwards Pty Limited Phase 3 Carboplatin with phenoxodiol or placebo for platinum-resistant or platinum-refractory, late-stage epithelial ovarian, fallopian or primary peritoneal cancer. Eligibility: Go to Clinical Trials.gov page Status: Recruiting Contact: Vicky Wegener 2. MORAb-003-004
A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse Sponsor: Morphotek / PPD Phase 3 Status: Recruiting Contact: Raymond Tangunan 3. MORAB-003-003 PR
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory Relapsed Ovarian Cancer Sponsor: Morphotek / Novotech Australia Phase 2 Status: Recruiting Contact: Raymond Tangunan
|